



October 15, 2025

Company Name: GNI Group Ltd.
Representative: Director, Representative Executive Officer,
President and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person: Director, Executive Officer, Vice President
COO and CFO
Ryosuke Matsui
(TEL. 03-6214-3600)

Notice of Phase 3 Trial Results of F351 (Hydronidone) at AASLD—The Liver Meeting® 2025

(Note) This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail.

GNI Group Ltd. ("the Company") announces that its key subsidiary, Gyre Therapeutics, Inc. ("GYRE"), will present the positive results from the positive Phase 3 clinical trial of Hydronidone (F351), a novel anti-fibrotic agent designed to inhibit hepatic stellate cell (HSC) activation and promote HSC apoptosis for the treatment of liver fibrosis associated with chronic hepatitis B. The presentation will take place at the American Association for the Study of Liver Diseases (AASLD) annual meeting, *The Liver Meeting® 2025*, to be held in Washington, D.C., from November 7–10, 2025.

This presentation has been selected as a "Poster of Distinction". A "Poster of Distinction" is awarded to the top 10% of all poster presentations at AASLD, recognizing abstracts that are considered to be of exceptional interest and significance.

GYRE's press release is available at the following link:

[Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025](#)